Reply to: “Review of drug-related causes of oculocutaneous disease” - 13/01/15

Doi : 10.1016/j.jaad.2014.10.018

Jonathan E. Mayer, BA ^a, M. Alan Menter, MD ^b,^⁎
^a Columbia University College of Physicians and Surgeons, New York, New York
^b Baylor University Medical Center, Dallas, Texas

^∗Correspondence to: M. Alan Menter, MD, Baylor University Medical Center, 3900 Junius St, Ste 125, Dallas, TX 75246

Le texte complet de cet article est disponible en PDF.

Funding sources: None.

Disclosure: Dr Alan Menter has reported the following financial relationships: Abbott Laboratories, consultant, honorarium; Abbott Laboratories, speaker, honorarium; Abbott Laboratories, principal investigator, honorarium; Abbott Laboratories, advisory board, grants/research funding; AbbVie, speaker, fees; Amgen, advisory board, grants/research funding; Amgen, speaker, honorarium; Astellas Pharma US, advisory board, honorarium, consultant, grants/research funding; Celgene Corporation, principal investigator, grants/research funding; Centocor Ortho Biotech, consultant, grants/research funding, advisory board, honorarium; Eli Lilly and Company, principal investigator, grants/research funding; Galderma Laboratories, advisory board, honorarium, speaker; Genentech, advisory board, grants/research funding; Novartis Pharmaceuticals, principal investigator, grants/research funding; Novo Nordisk A/S, principal investigator, grants/research funding; Pfizer, speaker, honorarium, advisory board, honorarium, principal investigator, grants/research funding; Promius Pharma, LLC, principal investigator, grants/research funding; Stiefel a GSK company, principal investigator, grants/research funding; Syntrix, principal investigator, grants/research funding; Warner Chilcott, advisory board, honorarium. Jonathan Mayer has no conflicts of interest to disclose.

Export

Vol 72 - N° 2

P. 362-363 - février 2015 Retour au numéro

Article précédent

Review of drug-related causes of oculocutaneous disease
Michael C. Cameron, Andrea L. Suárez, Patricia L. Myskowski

| Article suivant

Alitretinoin and Darier disease: “All that glisters is not gold”
Riccardo Balestri, Annalisa Patrizi, Federico Bardazzi

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

connectez-vous ou créez un compte

Reply to: “Review of drug-related causes of oculocutaneous disease” - 13/01/15

Export citations

Fichier

Contenu

Accès rapides

Mon compte

Aide & support

Plateformes Elsevier Masson

Déclaration CNIL